Intended Retirement of Independent Non-executive Director and changes of composition of board committees

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:​HCM, HKEX:​13) today announces that Professor Mok Shu Kam, Tony has informed the Company that he would not seek re-election after retiring from the Board at the forthcoming annual general meeting of the Company to be held on May 12, 2026 (“AGM”). Professor Mok has served as an Independent Non-executive Director of the Company for more than eight years, approaching the nine-year cap on the tenure of independent non-executive directors under the Hong Kong Listing Rules. Consequently, he will cease to be an Independent Non-executive Director of the Company at the conclusion of the AGM. Upon his retirement, he will also step down from his roles as chairman and member of the board committees of the Company.

GlobeNewsWire • Mar 6, 2026

HUTCHMED (China) Limited (HCM) Q4 2025 Earnings Call Transcript

HUTCHMED (China) Limited (HCM) Q4 2025 Earnings Call Transcript

Seeking Alpha • Mar 5, 2026

HUTCHMED to Announce 2025 Final Results

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Feb. 06, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2025 on Thursday, March 5, 2026 at 6:00 am Eastern Standard Time (EST) / 11:00 am Greenwich Mean Time (GMT) / 7:00 pm Hong Kong Time (HKT).

GlobeNewsWire • Feb 6, 2026

HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet

— First randomized Phase III trial confirming the efficacy of MET inhibition in patients with advanced NSCLC and acquired MET amplification after progression on prior EGFR-TKI treatment —

GlobeNewsWire • Jan 14, 2026

Positive China Trial Data Moves HUTCHMED Closer To Rare Blood Disorder Drug Filing In 2026

HUTCHMED (China) Limited (NASDAQ: HCM) on Tuesday shared data from the Phase 3 registration part of the ESLIM-02 clinical trial of sovleplenib in adult patients with warm antibody autoimmune hemolytic anemia (wAIHA).

Benzinga • Jan 7, 2026

Wall Street Analysts Predict a 55.93% Upside in HUTCHMED (HCM): Here's What You Should Know

The consensus price target hints at a 55.9% upside potential for HUTCHMED (HCM). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Investment Research • Jan 7, 2026

HUTCHMED Announces Positive Topline Results of Phase III Part of ESLIM-02 Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

— Delivers rapid, durable responses in wAIHA, the more common form of this potentially life-threatening disease —

GlobeNewsWire • Jan 7, 2026

HUTCHMED Initiates Phase III Stage of the Ongoing Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 05, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that it has initiated the Phase III part of the Phase II/III trial to evaluate the efficacy of the combination of surufatinib, camrelizumab, nab-paclitaxel and gemcitabine as a first-line treatment for patients with metastatic pancreatic ductal adenocarcinoma (“PDAC”) in China. The first patient received the first dose on December 30, 2025.

GlobeNewsWire • Jan 5, 2026

HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Savolitinib for the treatment of Gastric Cancer Patients with MET Amplification

— NDA supported by positive Phase II registration study data in Chinese patients; follows Breakthrough Therapy Designation granted in 2023 —

GlobeNewsWire • Dec 30, 2025

HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Fanregratinib in Second-Line Intrahepatic Cholangiocarcinoma

— NDA supported by results from a Phase II registration trial in China — — Second most common form of liver cancer after hepatocellular carcinoma, with generally poorer long-term survival in comparison — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Dec. 29, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that the New Drug Application (“NDA”) for fanregratinib (HMPL-453) for the treatment of adult patients with advanced, metastatic or unresectable intrahepatic cholangiocarcinoma (“ICC”) with fibroblast growth factor receptor (“FGFR”) 2 fusion/rearrangement who have previously received systemic therapy has been accepted and granted priority review by the China National Medical Products Administration (“NMPA”).

GlobeNewsWire • Dec 29, 2025